Lyell Immunopharma, Inc. (LYEL)
Nasdaq · Healthcare · Biotechnology
$9.07−2.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $222M
- 52-week range
- $8.69 – $45.00
- 52-week change
- −47.65%
- EPS (trailing)
- −$12.86
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 6, 2026
Fiscal year to Dec 2025
- Revenue
- $36K (−40.98%)
- Net income
- −$274M
- Operating margin
- −748333.3%
- Diluted EPS
- −$16.06
- Free cash flow
- −$151M
From the company’s annual report on SEC EDGAR.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Headquarters: South San Francisco, United States · 161 employees · lyell.com